GSK (LON:GSK) Earns Buy Rating from Shore Capital

GSK (LON:GSK - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Shore Capital in a report issued on Friday,Digital Look reports. They presently have a GBX 2,000 ($26.86) target price on the stock. Shore Capital's target price suggests a potential upside of 47.77% from the stock's current price.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research note on Friday. Berenberg Bank reissued a "hold" rating and issued a GBX 1,600 ($21.49) price objective on shares of GSK in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 1,450 ($19.47) target price on shares of GSK in a research report on Tuesday, July 8th.

GSK Trading Down 4.2%

Shares of LON GSK traded down GBX 59.50 ($0.80) during midday trading on Friday, hitting GBX 1,353.50 ($18.18). The stock had a trading volume of 392,537,375 shares, compared to its average volume of 16,499,305. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a 1-year low of GBX 1,242.50 ($16.68) and a 1-year high of GBX 1,678.68 ($22.54). The company has a market capitalization of £54.92 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 1.24 and a beta of 0.31. The company has a fifty day moving average price of GBX 1,435.91 and a 200 day moving average price of GBX 1,422.12.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insider Activity at GSK

In other GSK news, insider Wendy Becker acquired 545 shares of the stock in a transaction on Friday, June 20th. The stock was purchased at an average price of GBX 1,435 ($19.27) per share, for a total transaction of £7,820.75 ($10,501.88). Also, insider Emma Walmsley sold 5,473 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.46), for a total value of £79,303.77 ($106,490.90). In the last three months, insiders bought 1,905 shares of company stock valued at $2,732,835. Corporate insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.